key: cord-0959901-0fkdciju
authors: nan
title: Abstracts der 28. Jahrestagung der Deutschen Gesellschaft für Schlafforschung und Schlafmedizin e. V
date: 2020-10-01
journal: Somnologie (Berl)
DOI: 10.1007/s11818-020-00267-4
sha: 6344b4c558efa29f39c379fc1ea88cf61fe32519
doc_id: 959901
cord_uid: 0fkdciju

nan

Objectives: Polysomnography (PSG) or home sleep apnea testing (HSAT) with respiratory polygraphy are the current standard diagnostics for sleep disordered breathing (SDB). These systems require a multitude of sensors, are obtrusive and thus not suited for long-term monitoring. Recent advances in optical heart rate monitoring give promise for wearable devices which are low-cost and might be suitable for the early detection and ambulatory monitoring of SDB. Even though not expected to completely replace PSG or HSAT, such devices could allow for a reliable pre-screening over several consecutive nights in larger populations. We investigated the feasibility of a wearable device to measure oxygen saturation (SpO2), respiratory rate (RR) and cardiac interbeat intervals (IBI).

We compared a wrist-worn device against PSG on 66 subjects (27 healthy volunteers and 39 patients with sleep disorders) in a clinical study (NCT03823105) at the Inselspital (Bern, Switzerland). In parallel to an overnight PSG, accelerometer and optical heart activity were measured via CSEM's smartwatch device. From the watch-based signals, SpO2 [1] , RR [2] , [3] and IBIs [2] were estimated and compared to PSG-derived reference measurements in terms of RMS error (for SpO2) and mean absolute error (for RR and IBI). Results: Watch-based SpO2 estimates show an RMS error of ARMS = 3.2 % (after the automatic rejection of 15.8 % by our algorithm [4] ) which is compliant with the ISO 80601-2-61:2017 standard and FDA guidance for reflectance type sensors. Moreover, RR and IBI were estimated with a subject-wise mean absolute error of 1.55 ± 1.04 breaths/min and 6.54 ± 5.41 milliseconds.

The present results show promising performances for watchbased estimation of SpO2, RR and IBIs during sleep. Limited by a rather small dataset, this approach should be tested in a larger population, especially on patients with moderate to severe SDB. Future work will focus on combining SpO2, RR and IBI estimates to provide a low-cost solution for the early detection and long-term ambulatory monitoring of SDB. Objectives: Much interest has been raised in the apneic events during sleep in infants and children. Reference values on the frequency and duration of different types of apneas during sleep in normal subjects are sparse, most of which are from the 1980s and 1990s. As a rule, they cover limited numbers of observations. The study aimed to perform a meta-analysis of the frequency and duration of different types of apneas in infants and children in sleep based on contemporary publications. Methods: A systematic literature search in MEDLINE, Web of Science and Google Scholar was performed in February 2020 to identify studies conducted in 2000 through 2020 that described normative values of respiratory events during sleep in infants and children based on polysomnographic investigations. Using the PRISMA reporting guidelines, thirteen studies covering polysomnographic findings of 2563 participants reporting the values of the frequencies and durations of central, obstructive and mixed apneas during sleep in normal infants and children were identified. The mean age of the participants in the studies ranged from 0.6 through 140.4 months. Proportions of boys in the studies ranged between 30 and 64 %. A meta-analysis was performed for each of the measurements using OpenMetaAnalyst software (Brown University School of Public Health, Providence RI, US) in random-effect models. Reported or calculated mean values and standard deviations were analysed. Results: . Fig. 1 summarizes the findings on the mean frequencies of the different types of apneas per 1 h of sleep time (apnea indices) across the studies. Meta-regression found statistically significant association between mean central apnea index and mean child age (b = -0.012; p < 0.001), mean obstructive apnea index and mean child age (b = -0.002; p < 0.001), mean mixed apnea index and mean child age (b = -0.002; p = 0.019). No statistically significant associations were found between the mean values of the apnea indices and the percent of boys across the studies. . Fig. 2 is the summary of the mean apneas duration. Meta-regression failed to find associations between the mean central apnea length (p = 0.982), the mean mixed apnea length (p = 0.646) and the mean age of children. Significant association was found between the mean obstructive apnea length and the The expected 18-24 week wait time calculated from this "81 patients over 5 weeks" analysis is likely to be much longer, as absences were not taken into account. In a real life scenario, the waitlist would likely be around 8-14 months, which, from a patient perspective, is unacceptable. We suggest a novel triage concept consisting of a structured phonebased pre-screening (by booking clerk) and a virtual face-to-face triage visit to patients (by physician/nurse), including triage support to community health care providers via a written individualized report. Guided by a needs assessment concept, patients are coded red, yellow, and green, the latter standing for problems which could potentially be solved in the community by clinicians with guidance (e. g. providing evidence based interventions). The implementation of first line measures for category "green" (e. g. screening for familial iron deficiency) and harmonizing surveillance measures will enhance knowledge dissemination. Objectives: Residual Excessive Daytime Sleepiness (rEDS) occurs in up to 12 % of Obstructive Sleep Apnea (OSA) patients despite optimal continuous positive airway pressure (CPAP) therapy. This study assessed the efficacy and safety of pitolisant, a selective histamine H3-receptor antagonist waking agent in moderate to severe OSA treated by CPAP but exhibiting rEDS. Methods: In a multicentre, double-blind, randomized, placebo-controlled trial, Pitolisant was individually titrated up to 20 mg/day over 12 weeks. Primary endpoint was the Epworth Sleepiness Scale (ESS) score change in intention to treat. Key secondary endpoints were maintenance of wakefulness (Oxford Sleep Resistance Test (OSleR)), clinical global impressions of severity (CGI), patient's global opinion (PGO) and safety. Results: 244 OSA patients (mean age: 53.1 years, mean Apnoea+hypopnea index under CPAP: 4.18/hour, baseline ESS score: 14.7 (±2.9)) were randomized to Pitolisant (n = 183) and placebo (pl) (n = 61). ESS was significantly reduced with Pitolisant compared to pl -2.6 (95 % CI: [-3.9; -1.4]) (p < 0.001). The ratio of increase in mean latency during OSleR Tests sig-

A multi-center, two-stage, single-arm, prospective, first-night order cross-over, evaluator-blind study to evaluate the efficacy, safety and tolerance of the iNAP® sleep therapy system in adults with obstructive sleep apnea Objectives: Obstructive sleep apnea (OSA) occurs during sleep when the upper airway collapses during inspiration and remains closed despite continued inspiratory effort. Intraoral devices, with or without applied negative oral pressure, stabilize the oropharynx and have reduced the severity of OSA in selected patients. We are reporting results from a multi-center, prospective, first-night-order cross-over, study of the efficacy, safety and tolerance of the iNAP® Sleep Therapy System, a system that applies negative oral pressure. Methods: One hundred thirty (130 patients) fulfilled all the inclusion criteria and none of the exclusion criteria and completed a baseline and 1st treatment polysomnographic study (Tx PSG). Sixty-three (63) patients, who had a Total Sleep Time (TST) ≥ 4 h/night on the Baseline PSG Study, an oral negative vacuum time maintained by iNAP® ≥ 4 h/night and TST ≥ 4 h/night (1st Tx PSG Study), formed the Primary Endpoint (PE) cohort, and 54 of 63 patients completed a 2nd Tx PSG at least 28 days after the 1st Tx PSG. Results: Sixty-three adults (18~75 years, body-mass index < 33 kg/m2, oxygen desaturation index between 10~60 events/hr, and apnea hypopnea index (AHI) between 15~55 events/hr) formed the PE cohort. Thirty-three (33) of these patients (52 %; 95 % CI = 40-65 %, p < 0.001) responded to iNAP Tx 1st PSG (had a > 50 % reduction in AHI compared to baseline and treated AHI ≤20 events/hr). The reduction in AHI was durable; a similar number of patients maintained a response to iNAP on the 2nd Tx PSG 28 days later. iNAP therapy was associated with a significant increase in the average oxy-hemoglobin saturation during sleep, and a significant reduction in the average percent desaturation associated with apneas and hypopneas and the total sleep time spent with an oxy-hemoglobin saturation below 90 %. The incidence of adverse events was low, and all adverse events were self-limited. Patients tolerated the iNAP device well and used the device on average 5.6 h per night during the 28-day study period. Conclusions: The iNAP® Sleep Therapy System achieved a significant, durable clinical effect in a significant fraction of selected OSA patients with moderate to severe OSA with an excellent comfort and safety profile. Thus, approximately half of appropriately selected patients with moderate to severe OSA may be expected to benefit from treatment with the iNAP® Sleep Therapy System. Keywords: OSA, Oral negative pressure, Apnea hypopnea index, Therapy, Oxy-hemoglobin saturation ); these improvements were maintained for the study duration. Common adverse events (AEs; ≥5 %) included headache, nausea, insomnia, nasopharyngitis, dry mouth, anxiety, decreased appetite, and upper respiratory tract infection, and were similar in narcolepsy and OSA; 27 participants (4.2 %) had ≥1 serious AE. Conclusions: Solriamfetol demonstrated sustained improvements on functionality and work productivity measures for up to 52 weeks in participants with EDS associated with narcolepsy or OSA. Safety was similar in the narcolepsy and OSA subgroups. Keywords: JZP-110, Narcolepsy, OSA, Questionnaire, Clinical trial KV 23 Effects of solriamfetol on 24-hour blood pressure patterns in participants with excessive daytime sleepiness associated with obstructive sleep apnoea Objectives: Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the EU and US to improve wakefulness in adults with excessive daytime sleepiness associated with obstructive sleep apnoea (OSA; 37.5-150 mg/day). Previous solriamfetol studies reported small mean increases in blood pressure (BP) in participants with OSA. These analyzes evaluated the time course of these effects and effects on nocturnal decreases in BP ("dipping"; "non-dipping" is a risk factor for adverse cardiovascular outcomes) in participants with OSA. Methods: Twenty-four-hour ambulatory BP monitoring was conducted at baseline and Week 8 in a 12-week randomized controlled trial in participants treated with placebo or solriamfetol (37.5, 75, 150, or 300 mg/ day) (NCT02348606; EudraCT 2014-005514-31). Mean BP in 2-hour intervals across the day and the percentage of participants with non-dipping BP profiles were summarized (no formal statistical analyzes performed). Results: The safety population included 474 participants. At baseline, 50 % (placebo) and 49 % (combined solriamfetol) of participants had hypertension, and 51 % and 49 %, respectively, used antihypertensive medications. At Week 8, mean increases in BP were observed in the 75 and 300 mg groups from ~ 6 AM until 8 PM; increases in the 37.5 and 150 mg groups were minimal. At baseline, 58 % (placebo) and 55 % (combined solriamfetol) of participants were non-dippers (defined as <10 % decrease in mean arterial pressure during sleep). There was no increase in the percentage of non-dippers at Week 8 relative to baseline (placebo, 56 %; combined solriamfetol, 53 %). Results were similar when dipping was defined by changes in mean systolic or diastolic BP. During the study, no placebo-treated participants and 1 % of solriamfetol-treated participants initiated antihypertensive medication. One participant (receiving 150 mg solriamfetol) discontinued due to an adverse event (AE) of increased BP. Conclusions: At baseline, approximately half the study population had hypertension and/or used antihypertensive medications. Effects of solriamfetol on BP at the highest approved dose (150 mg/day) were transient across the day. The percentage of participants with a non-dipping BP profile did not increase with solriamfetol at any dose studied. Few participants initiated new antihypertensive medication or discontinued due to AEs of hypertension/increased BP. Keywords: JZP-110, Hypertension, Cardiovascular disease, Diastolic pressure, Systolic pressure bruchsraten bei Patienten, die Standardversorgung, TM-GC und zusätzlich ein Peng-Tool erhielten. Cox Proportional Hazard Modelle wurden entwickelt. Ergebnisse: 69.444 Patienten wurden analysiert (Alter 63 ± 13, männlich 73 %, versichert 86 %, APAP+CPAP 90 %, Bilevel/ASV 10 %, Nasenmaske 49 %, Nasenpolstermaske 13 % und Vollmaske 38 %). Die durchschnittliche Behandlungsdauer betrug 3,7 ± 1,8 h Jahre, die Therapieabbruchraten waren 29 % bei Standardversorgung, 19 % bei TM-GC und 11 % bei PENg-Tool (p < 0,001). Die Dynamik der Therapieabbrüche sind in . Abb. 1 aufgeführt. Schlussfolgerungen: Die Standardversorgung ist mit deutlich höheren mittelfristigen PAP-Therapie-Abbruchraten im Vergleich zur proaktiven TM-GC assoziiert und der zusätzliche Einsatz eines PE-Werkzeugs ist mit einer weiteren Reduktion der Therapieabbruchraten assoziiert. Unterstützt durch ResMed Germany Inc. Results: Neither the single plant extracts nor the combination or the reference drug LZ reduced the cell viability in the tested concentrations. The treatments did not stimulate TNF-a or IL-1b releases. The gene expression profiles of the four plant extracts, their combination and LZ could be clearly distinguished in the PCA-Analyses. The subsequent detailed gene expression analyses revealed that cytokines, neurotrophins (e. g. BDNF) and neurotransmitters were among the 2.500 genes with the most variable expression. The four plant extracts and the combination exhibited different expression profiles, also in comparison to LZ. Conclusions: The four plant extracts and their combination target in SH-SY5Y cells relevant genes for the modulation of the neurotrophic activity. Keywords: Sleep, Neurotrophines, Phytomedicine, SH-SY5Y Cells, Geneexpression-Analyses Objectives: Hearing is essential for communication in humans as well as other social mammals like mice or gerbils. Hearing loss cannot only lead to social deprivation but may also cause co-morbidities like tinnitus, an auditory phantom percept of a sound without physical source. It is known that noise induced hearing loss has a circadian component: In mice, hearing thresholds are significantly stronger affected when the acoustic trauma scheint. Dabei zeigte sich, dass der PUI willentlich in Richtung eines höheren Schläfrigkeitsgrades manipuliert werden konnte. In der vorliegenden Auswertung wurde überprüft, ob dieser Befund in der Gesamtstichprobe weiterhin Bestand hat und ob dieser Effekt möglicherweise geschlechtsspezifisch ist. Patienten und Methoden: Insgesamt haben 50 Studienteilnehmer/Innen (10 Frauen) im Alter zwischen 18 und 30 Jahren die Studie komplett durchlaufen. Unter anderem umfasste die Studie drei Termine unter kontrolliertem Schlafentzug [ein Kontrollschlafentzug (K-SE) gefolgt von zwei Experimentalschlafentzügen mit den Motivationsbedingungen "Wachheit wird belohnt" (W-SE) oder "Schläfrigkeit wird belohnt" (S-SE)]. An allen drei Terminen erfolgten sowohl am Abend direkt nach dem Eintreffen im Schlaflabor als auch am Morgen nach dem Schlafentzug zu individuell konstant gehaltenen Zeitpunkten 11-minütige PST-Messungen. Schlafentzugsbedingte Veränderungen des PUI unter Baselinebedingung aber auch unter Berücksichtigung einer in Aussicht gestellten finanziellen Belohnung wurden für Männer und Frauen getrennt mittels Wilcoxon-Vorzeichen-Rang-Test auf statistische Signifikanz geprüft. Ergebnisse: Für beide Geschlechter konnte nach dem K-SE im Mittel (Median) eine statistisch signifikante Zunahme des PUI über Nacht beobachtet werden (♂: 2, 27, 62, 4, 57, p = 0, 0086; ♀: 2, 34, IQR: 1, 07, 3, 17, p = 0, 0039) . Während der PUI auch nach dem S-SE für beide Geschlechter am Morgen durchschnittlich signifikant größer als am Abend war (♂: 3, 80, IQR: 1, 67, 8, 50, p < 0, 0001; ♀: 3, 41, IQR: 2, 46, 6, 04, p = 0, 0059) , erwies sich die PUI-Veränderung über Nacht nach dem W-SE nur bei den Männern als statistisch signifikant (♂: 1, 80, 77, 4, 52, p = 0, 0059; ♀: 0, 29, 21, 4, 86, p = 0, 6250 Fragestellung: Die innere Kündigung ist ein Zustand der kognitiven, emotionalen und behavioralen Distanzierung von der Arbeit, der sich v. a. durch mangelnde Eigeninitiative und Interesse auszeichnet. Forschungsergebnisse zu dem Konstrukt der inneren Kündigung liegen nur vereinzelt vor, da man sich bei der Untersuchung von Zusammenhängen mit gesundheitlichen Problemen vermehrt auf die Arbeitszufriedenheit und Burnout fokussiert hat. Ziel dieser Studie war es daher, den aktuellen Forschungsstand hinsichtlich der inneren Kündigung und ihren Zusammenhängen mit der Schlafqualität, depressiver Symptomatik, somatischer Beschwerden, Stress, Ressourcen und Lebensqualität zu erweitern. Fragestellung: In einer Onlineumfrage wurden nicht-selbstständige Ar-beitnehmerInnen befragt, die mindestens 17,5 h pro Woche arbeiteten. Die TeilnehmerInnen ordneten sich basierend auf einer vorgegebenen Definition entweder der Gruppe der innerlich Gekündigten oder der nicht innerlich Gekündigten zu. Die obengenannten Konstrukte wurden mittels Fragebögen erfasst. Die Stichprobe umfasste 252 ArbeitnehmerInnen (weiblich = 174, männlich = 76, divers = 2), wobei sich 52 Personen der Gruppe der innerlich Gekündigten und 200 Personen der Gruppe der nicht innerlich Gekündigten zuordneten. Ergebnisse: Personen, die innerlich gekündigt hatten, berichteten über eine signifikant geringere Schlafqualität, mehr depressive Symptome, mehr somatische Beschwerden, mehr Stress und eine geringere Lebenszufriedenheit. Darüber hinaus zeigten die Selbstauskünfte signifikant geringere Level an Hilfsbereitschaft, Gewissenhaftigkeit, Unkompliziertheit und Eigeninitiative im Vergleich zu den Personen, die nicht innerlich gekündigt hatten. Ein signifikanter Unterschied bzgl. des Arbeitsverhaltens konnte nicht gezeigt werden. Schlussfolgerungen: Die Studienergebnisse zeigen, dass auch hinsichtlich der Schlafqualität die Thematik der inneren Kündigung von hoher Relevanz ist, da jeder Fünfte der Befragten betroffen ist und erhebliche psychische und physische Beeinträchtigungen berichtet werden. Die Erkenntnisse können von ArbeitnehmerInnen als auch Unternehmen genutzt werden, um die Sensibilisierung und Relevanz präventiver Maßnahmen zu betonen. Schlüsselwörter: Innere Kündigung, Schlaf, Depression, Stress, Lebensqualität P 11 Zusammenhänge zwischen Schlafhygienewissen, Schlafhygiene und Schlafqualität in Abhängigkeit von Nachtschicht -eine Querschnittstudie *B. Klofat 1,2 , P. Gerlach 1 1 Hochschule Fresenius, Psychologie, Hamburg, Deutschland; 2 Heinrich-Heine-Universität, Klinische Psychologie, Düsseldorf, Deutschland is given during the night compared to rather mild effects on hearing when the trauma is applied during daytime. Last year we reported different circadian effects of an acoustic trauma in gerbils when it was applied during different time of day, now we added the effects during nighttime trauma. Methods: We investigate the effect of acoustic traumata (2 kHz, 115 dB SPL, 75 min) applied either at 9 AM, 1 PM, 5 PM or 12 PM on the hearing thresholds and tinnitus development of 31 male Mongolian gerbils (Meriones unguiculatus). Hearing thresholds were measured by acoustic brainstem response (ABR) audiometry at 10 AM one day before and one week after the trauma and possible tinnitus percepts were behaviorally assessed by the gap prepulse inhibition of the acoustic startle (GPIAS) at 9 AM one day before and one week after the trauma. Results: We find daytime dependent changes of the trauma on mean hearing thresholds in a frequency dependent manner by one-and two-factorial ANOVAs with the maximum hearing loss (HL) one octave above the trauma frequency (F(3,104) = 3.42, p = 0.02), and-comparable to the results in mice-significant time dependent effects at the trauma frequency. We find a minimal HL after the 9 AM trauma and the maximal HL after the 5 PM and the 12 PM traumata (F(6,46) = 2.79, p = 0.02). Additionally to the HL effects we find correlations of these threshold changes with the strength of the tinnitus percept (effect size of GPIAS) in the 5 PM trauma group (p = 0.02) and a trend in the 12 PM trauma group (p = 0.07), i. e., animals with stronger tinnitus percepts showing better hearing thresholds than animals with light or no phantom percepts. Conclusions: Taken together, also in gerbils circadian sensitivity of the hearing thresholds to noise trauma can be found and tinnitus strength correlates with it only when the trauma is applied at the most sensitive time, namely in the evening and night. Keywords: Grundlagenforschung, Nager, Verhaltensmessungen, BERA, Hörsystem P 9 Eine Subgruppenanalyse zu den Unterschieden in polysomnographischen Parametern zwischen Schicht-und Tagarbeitenden mit Insomnie. *J. Ell, B. Feige, D. Riemann, K. Spiegelhalder Universitätsklinik Freiburg, Psychiatrie und Psychotherapie, Freiburg, Deutschland Fragestellung: Schichtarbeiter/innen leiden häufig unter insomnischen Symptomen. Dabei berichten sie subjektiv ähnliche Schlafparameter wie Arbeitnehmer/innen mit Insomnie, welche nicht in Schichtarbeit tätig sind. Um ein umfassendes Bild der Insomnie im Kontext Schichtarbeit zu erhalten, wurden in dieser Studie objektive Schlafparameter von Schichtarbeitenden mit denen von Tagarbeitenden verglichen. Patienten und Methoden: Für die Analyse wurden Daten aus dem Zeitraum zwischen 1999 und 2020 des Schlaflabors der Abteilung Psychiatrie und Psychotherapie am Universitätsklinikum Freiburg gesichtet. In die Analyse wurden Personen eingeschlossen, welche die Kriterien einer Insomnie nach DSM-5 Kriterien erfüllten, keine den Schlaf beeinflussende Medikamente einnahmen sowie an keiner komorbiden psychischen oder körperlichen Erkrankung litten. Die polysomnographischen Daten von 11 Nachtschichtarbeitenden (18,2 % weiblich; M Alter = 40,7 Jahre) und 12 Schichtarbeitenden ohne Nachtschicht (50,0 % weiblich; M Alter = 42,9 Jahre) wurden erfasst und mit den Daten von 23 Tagarbeitenden (gematcht für Alter und Geschlecht) verglichen. Hierzu wurden multivariate ANCO-VAs mit der Kontrollvariable Geschlecht berechnet. Ergebnisse: Es konnten keine signifikanten Unterschiede zwischen den Gruppen bezüglich ihrer Schlafkontinuität gefunden werden. Die Gruppen unterschieden sich somit nicht in der Dauer ihres Schlafes (F 2,42 = 1,46, p = 0,244), der Schlafeffizienz (F 2,42 = 1,27, p = 0,304), der Einschlaflatenz (F 2,42 = 0,64, p = 0,530), der Häufigkeit des Aufwachens während der Nacht (F 2,42 = 0,64; p = 0,531), der Dauer der Wachphasen nach dem Einschlafen (F 2,42 = 1,36, p = 0,267) sowie im Arousal Index (F 2,40 = 2,26; p = 0,117). Auch bei Betrachtung der Schlafarchitektur zeigten sich keine signifikanten Unterschiede bei gleichen Anteilen von N1 (F 2,42 = 0,35; p = 0,710), N2 scher Sicht sollte ohnehin Verhältnisprävention Vorrang haben z. B. Hinterfragen von ND-Systemen oder NDe passend zum Chronotyp. Schlüsselwörter: Schlafhygiene, Nachtschicht, Schlafqualtät, Schlafwissen, Schlafverhalten P 12 Weiterentwicklung und Anwendung eines normbasierten Index zur Messung objektiver Schlafqualität Musculoskeletal pain as a marker of health quality. Findings from the epidemiological sleep study among the adult population of Sao Paulo city. PLoS ONE 10 (11) Objectives: Erythropoietic protoporphyria is a rare dermatologic disease associated with acute phototoxicity and limited therapy options. Its far reaching impact on various aspects in life, including sleep, is yet to be fully unraveled. Methods: In our validated-questionnaire-based study we asked 12 patients with Erythropoietic protoporphyria (EPP) to rate their insomnia (insomnia severity index; ISI), their daytime sleepiness (Epworth Sleepiness Scale, ESS), their quality of life (DLQI), their anxiety and depression (hospital anxiety and depression scale), and their general well-being (WHO questionnaire and general health questionnaire) before treatment with afamelanotide and at 3 consecutive visits during spring, summer and winter time. Furthermore, we asked them to name possible reasons for their sleeping problems. Results: All of the patients reported pain and burning as a major problem during sleep. We saw a significant impact on quality of life, anxiety and depression, as well as an increase in the ISI score and in the ESS. We saw an improvement under therapy, but nonetheless season-dependent differences. adults with OSA who use or have attempted to use therapy to treat the underlying airway obstruction (approved dose range, 37.5-150 mg/day). This study evaluated the effects of solriamfetol on on-road driving performance in participants with EDS associated with OSA. Methods: In each period of this randomised, double-blind, placebo-controlled, crossover study (NCT02806895/EudraCT 2015-003930-28), driving performance during an on-road driving test was assessed at 2 h and 6 h post-dose following 7 days of treatment with solriamfetol (150 mg/ day × 3 days, then 300 mg/day × 4 days) or placebo. The primary endpoint-standard deviation of lateral position (SDLP), a measure of "weaving" (departure from a steady lane position), at 2 h post-dose-was compared between solriamfetol and placebo using a repeated mixed-effects analysis of variance model. 

Concealed, unobtrusive ear-centered EEG acquisition: cEEGrids for transparent EEG

Unobtrusive ambulatory EEG using a smartphone and flexible printed electrodes around the ear

Zeitspanne seit LTX 1 Monat bis zu 11 Jahren) in eine prospektive Studie ein. Indikationen für die Lungentransplantationen waren chronisch obstruktive Lungenerkrankung (n = 28), Idiopathische Lungenfibrose (n = 14), Cystische Fibrose (n = 8) und andere (n = 24)

Bei einem AHI ≥ 15/h als Cut-off-Wert zur Ermittlung von SBAS verstarben 17 von 47 Patienten mit und 9 von 27 ohne SBAS (33,3 % vs. 36,1 %

United States Objectives: Excessive daytime sleepiness (EDS) in patients with obstructive sleep apnoea (OSA) is associated with an increased risk of driving accidents. Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved in the EU and US to improve wakefulness and reduce EDS in R Ramaekers

Objectives: Neurotrophins such as the brain derived neurotrophic factor (BDNF) as well as cytokines play an important role in neuroprotection, the control of the central nervous system, and change with different sleep patterns. We questioned whether the plant extracts of Ballota nigra L, Crataegus oxycantha L, Passiflora incarnata L. and Valeriana officinalis L. alone or in combination can modulate the pro-inflammatory cytokines, neurothrophines or neurotransmitters in vitro. Methods: Synchronized human neuroblastoma SH-SY5Y cells were treated with the different aequeous plant extracts (5-400 µg/ml) alone and in combination (1/1/4/1). As reference drug Lorazepam (LZ) was used. Resazurin was used to determine cell viability. TNF-alpha and IL-1ß were estimated in the supernatant by ELISA. An unbiased transcriptomic approach was used to determine the overall gene expressions induced by the different plant extracts/combination. Deepsequencing data were evaluated with different tools including Principal Component Analysis (PCA) and differential gene expressions.